{"nctId":"NCT00294671","briefTitle":"The Effect of Diflunisal on Familial Amyloidosis","startDateStruct":{"date":"2006-02"},"conditions":["Familial Amyloid Polyneuropathy","Familial Amyloidosis"],"count":130,"armGroups":[{"label":"Diflunisal","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: diflunisal"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: placebo"]}],"interventions":[{"name":"diflunisal","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18 to 75 years\n* Biopsy proven amyloidosis\n* Genotyping of variant transthyretin\n* Signs of peripheral or autonomic neuropathy\n\nExclusion Criteria:\n\n* Use of other non-steroidal anti-inflammatory drugs\n* Other causes of sensorimotor polyneuropathy\n* Anticipated survival \\<2 years or liver transplantation in \\<1 yr\n* Liver transplantation\n* Profound nerve, heart or kidney impairment\n* Pregnancy or unwillingness to use contraception by women of childbearing age\n* Active or recent gastrointestinal bleeding\n* Non-steroidal or aspirin drug allergy/hypersensitivity","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Neurologic Impairment Score + 7 (NIS+7)","description":"The primary endpoint, the difference in polyneuropathy progression between treatments, was measured by the Neuropathy Impairment Score plus 7 nerve tests (NIS+7) which ranges from 0 (no neurologic deficits) to 270 points (no detectable peripheral nerve function).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null},{"groupId":"OG001","value":"26.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null},{"groupId":"OG001","value":"12.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Kumamoto Neurologic Scale;","description":"Change from baseline of the Kumamoto Score (0-102 points, increasing with disease severity), a clinical neurologic scale of motor, sensory, and autonomic function combined with heart and kidney end organ measures developed to track disease progression in Familial Amyloid Polyneuropathy (ATTR-FAP)","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"8.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"4.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Modified Body Mass Index (mBMI);","description":"The product of body mass index (BMI) and serum albumin level (g/L) \\[kg/M2xg/L\\].","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.7","spread":null},{"groupId":"OG001","value":"-67.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.7","spread":null},{"groupId":"OG001","value":"-38.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life Questionnaire: SF-36 Physical Component Score","description":"The 36 item short-form health survey (SF-36) was used to assess the difference between treatment groups for change of physical component scores over 2 years treatment. Range 0-100; lower scores reflect lower quality-of-life.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"-4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null},{"groupId":"OG001","value":"-1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life Questionnaire: SF-36 Mental Component Score","description":"The 36 item short-form health survey (SF-36) was used to assess the difference between treatment groups for change of mental component scores over 2 years treatment. Range 0-100; lower scores reflect lower quality-of-life.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null},{"groupId":"OG001","value":"-0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":64},"commonTop":["Infections","GI disorders","Nervous system disorders","Musculoskeletal and connective tissue disorders","General disorders"]}}}